ClinicalTrials.gg
CompletedNCT01887600ALPSUpdated Nov 14, 2024Results posted

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

A Phase 3 interventional study of Roxadustat and Placebo in Anemia in Chronic Kidney Disease in Non-dialysis Patients, sponsored by Astellas Pharma Europe B.V.. Completed at 138 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
8th of 43
594 · median 154
Started
2013
the only one that year
Phase 3
25 of 43
1 open now
Registered
10th of 43
by date
Lead sponsor
3 of 43
Astellas Pharma Europe B.V.

Among the 43 studies testing roxadustat in Anemia, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 25 in phase 3, and was the 10th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood. The purpose of the study was to see if Roxadustat is both effective and safe as a treatment for anemia in patients with chronic kidney disease.

Read the detailed description

The study consisted of three study periods as follows:

  • Screening period: up to 6 weeks
  • Treatment period: minimum 52 weeks (primary treatment period) up to a maximum of 104 weeks (extended treatment period)
  • Post-Treatment Follow-Up period: 4 weeks
03

Conditions studied

  • Anemia in Chronic Kidney Disease in Non-dialysis Patients

Keywords

  • anemia
  • chronic kidney disease (CKD)
  • Hemoglobin (Hb)
  • non-dialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a diagnosis of chronic kidney disease, with Kidney Disease Outcomes Quality Initiative (KDOQI) Stage 3, 4 or 5, not receiving dialysis; with an Estimated (eGFR) \<60 mL/min/1.73 m\^2 estimated using the abbreviated 4-variable Modification of Diet in Renal Disease (MDRD) equation.
  • The mean of the Participant's three most recent values during the Screening period, obtained at least 4 days apart, must be less than or equal to 10.0 g/dL, with a difference of less than or equal to 1.0 g/dL between the highest and the lowest values. The last Hb value must be within 10 days prior to randomization.
  • Participant has a ferritin level greater than or equal to 30 ng/mL (greater than or equal to 67.4 pmol/L) at screening.
  • Participant has a transferrin saturation (TSAT) level greater than or equal to 5% at screening.
  • Participant has a serum folate level greater than or equal to lower limit of normal at screening.
  • Participant has a serum vitamin B12 level greater than or equal to lower limit of normal at screening.
  • Participant's (ALT), aspartate aminotransferase (AST) levels are less than or equal to 3 x (ULN), and total (TBL) is less than or equal to 1.5 x ULN.
  • Participant's body weight is 45.0 kg up to a maximum of 160.0 kg.

Exclusion criteria

Exclusion criteria:

  • Participant has received any ESA treatment within 12 weeks prior to randomization.
  • Participant has had more than one dose of IV iron within 12 weeks prior to randomization.
  • Participant has received a RBC transfusion within 8 weeks prior to randomization.
  • Participant has a known history of myelodysplastic syndrome or multiple myeloma.
  • Participant has a known hereditary hematologic disease such as thalassemia or sickle cell anemia, pure red cell aplasia, or other known causes for anemia other than CKD.
  • Participant has a known hemosiderosis, hemochromatosis, coagulation disorder, or hypercoagulable condition.
  • Participant has chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus erythematosus, rheumatoid arthritis, celiac disease) even if it is currently in remission.
  • Participant is anticipated to have elective surgery that is expected to lead to significant blood loss or anticipated elective coronary revascularization.
  • Participant has active or chronic gastrointestinal bleeding.
  • Participant has received any prior treatment with roxadustat or a hypoxia-inducible factor Prolyl Hydroxylase Inhibitor (HIF-PHI).
  • Participant has been treated with iron-chelating agents within 4 weeks prior to randomization.
  • Participant has a history of chronic liver disease (e.g., cirrhosis or fibrosis of the liver)
  • Participant has a known Class III or Intravenous (IV) congestive heart failure.
  • Participant has had a myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (e.g., pulmonary embolism) within 12 weeks prior to randomization.
  • Uncontrolled hypertension or two or more blood pressure (BP) values of systolic BP (SBP) greater than or equal to 160 mmHg or diastolic BP (DBP) greater than or equal to 95 mmHg confirmed by repeat measurement within 2 weeks prior to randomization.
  • Participant has a diagnosis or suspicion (e.g., complex kidney cyst of Bosniak Category 2F or higher) of renal cell carcinoma on renal ultrasound within 12 weeks prior to randomization.
  • Participant has a history of , except the following: cancers determined to be cured or in remission for greater than or equal to 5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps.
  • Participant is positive for any of the following: (HIV); surface antigen (HBsAg); or anti- virus antibody (anti-HCV Ab).
  • Participant has an active infection manifested by White Blood Count (WBC) > , and/or fever, in conjunction with clinical signs or symptoms of infection within one week prior to randomization.
  • Participant has a known untreated proliferative diabetic retinopathy, diabetic macular edema, macular degeneration and retinal vein occlusion.
  • Participant has had any prior organ transplant (that has not been explanted) or a scheduled organ transplantation.
  • Participant has participated in any interventional clinical study or has been treated with any drugs within 30 days or 5 half lives or limit set by national law, whichever is longer, prior to the initiation of Screening.
  • Participant has an anticipated use of dapsone in any dose amount or chronic use of acetaminophen (paracetamol) > 2.0 g/day during the treatment or follow-up period of the study.
  • Participant has a history of alcohol or drug abuse within 2 years prior to randomization.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
594 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants received roxadustat according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for at least 52 weeks up to a maximum of 104 weeks.

    Drug: Roxadustat

  • Placebo comparator
    Placebo

    Participants received matching placebo according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received matching placebo for at least 52 weeks up to a maximum of 104 weeks.

    Drug: Placebo

Interventions

  • Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.

    Also known as: ASP1517, FG-4592

  • DrugPlacebo

    Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response

    Hemoglobin (Hb) response was measured as Yes or No. Response Yes (responders) was defined as: Hb ≥11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL, for participants with baseline Hb \> 8.0 g/dL; or Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at two consecutive visits with available data separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell (RBC) transfusion, erythropoiesis-stimulating agent (ESA), or intravenous (IV) iron prior to Hb response. This was the primary efficacy endpoint for EU (EMA).

    Time frame: Baseline to week 24

  2. Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue Therapy

    The change from baseline to the average Hb values across weeks 28 to 52 without having received rescue therapy. The Hb values from visit windows at weeks 28, 32, 36, 40, 44, 48 and 52 were used for the calculation of the average of weeks 28 to 52. This was the primary efficacy endpoint for US (FDA).

    Time frame: Baseline and weeks 28 to 52

Secondary outcomes

  1. Hb Change From BL to the Average Hb in Weeks 28-36 Without Having Received Rescue Therapy Within 6 Weeks Prior to and During 8-Week Evaluation Period

    The Hb values from visit windows at weeks 28, 32 and 36 were used for the calculation of the average of weeks 28 to 36.

    Time frame: Baseline and weeks 28 to 36

  2. Change From BL in Low-Density Lipoprotein (LDL) Cholesterol (Regardless of Fasting Status) to the Average LDL Cholesterol of Weeks 12 to 28

    Analysis was completed on all values collected on day 1 and weeks 12, 20 and 28.

    Time frame: Baseline and weeks 12 to 28

  3. Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron)

    The time to first use of rescue therapy was calculated (in years) as: (First event date - Analysis date of first dose intake + 1) / 365.25. The First event date was defined as Date of first dose of rescue medication during the efficacy emergent period and Analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1. The Efficacy Emergent Period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or the end of treatment (EOT) visit, whichever occurred first. Data reported was analysed by Kaplan-Meier estimate for cumulative proportion. Medication onset date was the date of the first use of rescue medication.

    Time frame: Baseline to week 104 (End of Treatment [EOT])

  4. Change From BL in Short Form (SF)-36 Vitality (VT) Sub-score to the Average VT Sub-score of Weeks 12 to 28

    Change from BL in SF-36 VT sub-score to the average value in weeks 12-28 was calculated using the physical component scores (PCS) of SF-36. The multi-purpose, short-form health survey has 36 questions with an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. The survey measures eight dimensions or scales: (1) physical functioning (PF) (10 items); (2) role limitations due to physical health problems (RP) (3 items); (3) bodily pain (BP) (2 items); (4) social functioning (SF) (2 items); (5) general health perceptions (GH) (5 items); (6) role limitations due to emotional problems (RE) (3 items); (7) vitality, energy or fatigue (VT) (4 items); and (8) mental health (MH) (5 items). The SF-36 scores ranged from 0-100 with higher scores indicating better health status.

    Time frame: Baseline and weeks 12 to 28

  5. Change From BL in SF-36 Physical Functioning (PF) Sub-score to the Average PF Sub-score of Weeks 12 to 28

    Change from baseline in SF-36 PF normalized sub-score compared to the average PF sub-score of weeks 12 to 28. The multi-purpose, short-form health survey has 36 questions with an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Change from baseline in PF sub score of SF-36 to the average of weeks 12-28 was compared by treatment arm for all participants (primary analysis) and in the subsets of participants with baseline PF sub score below 35 and equal or above 35. The SF-36 scores ranged from 0-100 with higher scores indicating better health status. All available SF-36 PF values were used i.e., both scheduled and unscheduled for the calculation of the average PF sub-score of weeks 12 to 28.

    Time frame: Baseline and weeks 12 to 28

  6. Change From BL in Mean Arterial Pressure (MAP) to the Average MAP of Weeks 20 to 28

    The MAP was derived for each visit from the average systolic (SBP) and diastolic blood pressure (DBP) calculated for each visit using the three readings and the following equation: MAP = (2/3) \* DBP + (1/3) \* SBP. Baseline assessment was the assessment on day 1 (average of the three readings). If the baseline assessment was missing, then the latest available value prior to first drug administration was used.

    Time frame: Baseline and weeks 20 to 28

  7. Time to First Occurrence of Hypertension

    Occurrence of hypertension was defined as SBP increase from BL ≥20 mmHg and SBP \>170 mmHg or DBP increase from BL ≥15 mmHg and DBP ≥110 mmHg. Time to first occurrence of hypertension was defined as first date where SBP criterion or DBP criterion is met, whichever occurred first. Data was analysed using Kaplan-Meier estimate for cumulative proportion.

    Time frame: Baseline and year 0.5, year 1, year 1.5 and year 2

  8. Rate of Progression of CKD Measured by Annualized Estimated Glomerular Filtration Rate (eGFR) Slope Over Time

    Annualized eGFR slope over time was estimated by a random slopes and intercepts model using all available eGFR values (one baseline and all post-treatment values up to EOT period or start of dialysis adjusted on baseline Hb, region, CV history at baseline and the interaction terms (baseline eGFR by timepoint and baseline Hb by timepoint). All assessments collected after initiation of chronic dialysis (acute or chronic) are excluded from the analysis. Baseline assessment was the assessment from day 1 visit. If this value was missing, the value from screening visit was used.

    Time frame: Baseline to week 108

  9. Average Level of Hb Over Weeks 28 to 36 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period

    All scheduled and unscheduled hemoglobin values from weeks 28 to 36 were taken into account for calculating the average values.

    Time frame: Weeks 28 to 36

  10. Average Level of Hb Over Weeks 44 to 52 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period

    All scheduled and unscheduled hemoglobin values from weeks 44 to 52 were taken into account for calculating the average values.

    Time frame: Weeks 44 to 52

  11. Average Level of Hb Over Weeks 96 to 104 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period

    All scheduled and unscheduled hemoglobin values from weeks 96 to 104 were taken into account for calculating the average values.

    Time frame: Weeks 96 to 104

  12. Time to Achieve the First Hb Response Without Rescue Therapy, as Defined by Primary Endpoint

    Hb response was measured as Yes or No; Yes was defined as Hb ≥11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL, for participants with baseline Hb \> 8.0 g/dL; or Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL. For a participant without rescue therapy before Hb response (defined in 1 primary outcome), the time to achieve Hb response was calculated (in weeks) as: (First event date - Analysis date of first dose intake + 1) / 7 where First event date was defined as First date of both values that met the criteria for response. Participants who discontinued or received rescue therapy prior to the first Hb response or before the second consecutive Hb value defined as a response were classified as non responders and were censored at week 24 or end of efficacy emergent period, whichever came first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

    Time frame: Baseline to week 24

  13. Hb Change From BL to Each Post-Dosing Time Point

    All scheduled and unscheduled hemoglobin values that belong to each visit window were taken into account using one value per analysis window. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).

    Time frame: Baseline (day 1) and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104

  14. Hb Change From BL to the Average Hb Value of Weeks 28-36 Regardless of the Use of Rescue Therapy

    The Hb values from visit windows from weeks 28 to 36 were used for the calculation of the average regardless of rescue therapy. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dosing).

    Time frame: Baseline and weeks 28 to 36

  15. Hb Change From BL to the Average Hb Value of Weeks 44-52 Regardless of the Use of Rescue Therapy

    The Hb values from visit windows from weeks 44 to 52 were used for the calculation of the average regardless of rescue therapy. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dosing).

    Time frame: Baseline and weeks 44 to 52

  16. Hb Change From BL to the Average Hb Value of Weeks 96-104 Regardless of the Use of Rescue Therapy

    The Hb values from visit windows from weeks 96 to 104 were used for the calculation of the average regardless of rescue therapy. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dosing).

    Time frame: Baseline and weeks 96 to 104

  17. Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 28-36 Without Use of Rescue Therapy

    The percentage of Hb values measured during weeks 28-36 within 10.0 -12.0 g/dL, without having received rescue therapy within 6 weeks prior to and during the 8-week evaluation period is reported.

    Time frame: Baseline and weeks 28 to 36

  18. Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 44-52 Without Use of Rescue Therapy

    The percentage of Hb values measured during weeks 44-52 with values within 10.0 - 12.0 g/dL, without having received rescue therapy within 6 weeks prior to and during the 8-week evaluation period is reported.

    Time frame: Baseline and weeks 44 to 52

  19. Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 96-104 Without Use of Rescue Therapy

    The percentage of Hb values measured during weeks 96-104 within 10.0 -12.0 g/dL, without having received rescue therapy within 6 weeks prior to and during the 8-week evaluation period is reported.

    Time frame: Baseline and weeks 96 to 104

  20. Time to First Hospitalization

    Time to first hospitalization was defined in years as the First event date during the Efficacy Emergent Period - (Analysis date of first dose intake +1)/365.25. The first event date was defined as the Date of first admission. The Efficacy Emergent Period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. Analysis date of first dose intake was defined as the date of first study drug intake collected on day 1 visit. For participants who experienced more than one hospitalization, only their first event following study treatment was used. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

    Time frame: Baseline to week 104

  21. Number of Days of Hospitalization Per Patient Exposure Year (PEY)

    The sum of the durations of all hospitalizations in days was adjusted for the duration of exposure. Derived only for participants with at least one hospitalization. The number of days of hospitalization per PEY was calculated as the sum of the durations of all hospitalizations in days \[Minimum (Date of discharge, End of Efficacy Emergent Period) - Date of admission + 1\] / \[Duration of Efficacy Emergent Period in days / 365.25\]. Participants can have more than one hospitalization.

    Time frame: Baseline to week 104

  22. Time to First Use of Rescue Therapy (Composite of RBC, Transfusions, ESA Use, and IV Iron) in the First 24 Weeks of Treatment

    Time to first use of rescue therapy in years. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

    Time frame: Baseline to week 24

  23. Time to First Use of RBC Transfusions

    Time to First Use of RBC Transfusions during efficacy emergent period. For participants who have experienced more than one RBC transfusion, only their first event following study treatment was used. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

    Time frame: Baseline to week 104

  24. Mean Monthly Number of RBC Packs

    During efficacy emergent period, the mean monthly number of RBC packs was calculated as the sum of units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. In case of missing number of packs, values were estimated based on 1 unit for packed cells = 250 mL or 1 unit for whole blood = 500 mL. Participants without RBC transfusion were included with a value of zero. No estimation if values were missing.

    Time frame: Baseline to week 104

  25. Mean Monthly Volume of Blood Transfused

    During efficacy emergent period, the mean monthly volume of blood transfused was calculated as the sum of blood volume transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occurred first. The mean monthly volume transfused was calculated as the sum of the volume transfused between the first dose and up to the last dose in the period divided by duration (in days) and multiplied by 28 days. Participants without RBC transfusion were included with a value of zero.

    Time frame: Baseline to week 104

  26. Time to First Use of ESA Rescue Therapy

    Time to First Use of ESA Rescue Therapy during efficacy emergent period. For participants with use of ESA, the time to first use of ESA was calculated as (First event date - Analysis date of first dose intake + 1) / 365.25. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. Participants without ESA rescue were censored at the end of treatment.

    Time frame: Baseline to week 104

  27. Time to First Use of IV Iron

    Time to first use of IV iron during efficacy emergent period in years. For participants with use of IV iron, the time to first use of IV iron was calculated as (First event date - Analysis date of first dose intake + 1) / 365.25. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occurred first.Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

    Time frame: Baseline to week 104

  28. Change From BL to Each Post-Dosing Visit in Total Cholesterol

    Change from baseline to each planned assessment for total cholesterol is reported. Baseline was defined as the value on day 1. If the value was missing, the latest value prior to first study drug administration was used.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104

  29. Change From BL to Each Post-Dosing Visit in Low Density Lipoprotein (LDL)/High-Density Lipoprotein (HDL) Ratio

    Change from baseline to each planned assessment for LDL/HDL ratio is reported. Baseline was defined as the value on Day 1. If this value was missing, the latest value prior to first study drug administration was used.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104

  30. Change From BL to Each Post-Dosing Visit in Non-HDL Cholesterol

    Change from baseline to each planned assessment for non-HDL is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104

  31. Change From BL to Each Post-Dosing Visit in Apolipoproteins A1 (ApoA1)

    Change from baseline to each planned assessment for apolipoproteins A1 is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104

  32. Change From BL to Each Post-Dosing Visit in Apolipoproteins B (ApoB)

    Change from baseline to each planned assessment for apolipoproteins B is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104

  33. Change From BL to Each Post-Dosing Visit in Ratio ApoB/ApoA1

    Change from baseline to each planned assessment for ratio of ApoB/ApoA1 is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104

  34. Percentage of Participants With Mean LDL Cholesterol <100 mg/dL Calculated Over Weeks 12 to 28

    Mean LDL cholesterol \<100 mg/dL over weeks 12 to 28 was defined as a binary variable (Yes/No), where Yes was defined as mean LDL cholesterol \<100 mg/dL over weeks 12 to 28. Participants without any LDL value within this duration were excluded.

    Time frame: Weeks 12 to 28

  35. Percentage of Participants Who Have Achieved Antihypertensive Treatment Goal in CKD Participants Over Weeks 12-28

    Occurrence of achieved antihypertensive treatment goal was defined as the average SBP \< 130 mmHg and the average DBP \< 80 mmHg over the period of weeks 12-28. Participants without any blood pressure measurement were excluded.

    Time frame: Weeks 12 to 28

  36. Change From BL to the Average Value of Weeks 12-28 in Quality of Life (QoL) SF-36 Physical Component Score (PCS)

    The 36-Item short-form health survey (SF-36) is a multi-purpose survey with 36 questions. It provides an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. For each scale scores range from 0-100. The physical component score was calculated based on the results of the SF-36 scores. Higher scores indicate better health status.

    Time frame: Baseline and weeks 12 to 28

  37. Change From BL to the Average Value of Weeks 12-28 in Anemia Subscale (Ans) of Functional Assessment of Cancer Therapy (FACT-An) Score

    Baseline FACT-An AnS was defined as the FACT-An AnS value on Day 1. Together with the Functional Assessment of Cancer Therapy - General (FACT-G), the Anemia Subscale (AnS) is referred to as the FACT-An Total. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The Anemia AnS score range is 0 to 80. For the above score, a higher score indicates better QoL.

    Time frame: Baseline and weeks 12 to 28

  38. Change From BL to the Average Value of Weeks 12-28 in Total FACT-An Score

    Baseline FACT-An Total Score was defined as the FACT-An Total score on Day 1. Total Fact-An score is composed of FACT-G and Ans scales. FACT-G contains 27 items that cover four dimensions of well-being: physical (PWB) - 7 items, functional (FWB) - 7 items, social/family (SWB) - 7 items, and emotional (EWB) - 6 items. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The total score is obtained by summation of the scores from PWB, SWB, EWB, FWB and AnS. The FACT-An Total Score scale range is 0-188. A higher score indicates better QoL.

    Time frame: Baseline and weeks 12 to 28

  39. Change From BL to the Average Value of Weeks 12-28 in the Euroqol Questionnaire - 5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score

    The Euroqol Questionnaire - 5 Dimensions 5 Levels (EQ-5D 5L) is a self-reported questionnaire. The EQ-5D 5L is used as a measure of respondents' Health Related Quality of Life (HRQoL). The EQ-5D 5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D 5L descriptive system comprises of 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, extreme problems. The VAS records the respondent's self-rated health status on a graduated (0-100) scale, where the answers are labeled 'Best imaginable health state' and 'Worst imaginable health state' with higher scores for higher HRQoL.

    Time frame: Baseline and weeks 12 to 28

  40. Change From BL to the Average Value of Weeks 12-28 in Overall Work Impairment Due to Anaemic Symptoms

    Work productivity and activity impairment: anemic symptoms (WPAI:ANS) questionnaire version 2 was used to measure work and activity impairment during the last seven days due to anemia. It is self-assessed questionnaire which consists of 6 questions covering work and daily activities. Questions include asking if participant is working, how many hours the person missed work due to anemic symptoms, how many hours the person missed work due to other reasons, how many hours participant actually worked and how the anemic symptoms impacted their productivity and ability to do daily activities. For the last 2 questions, they were scored from 0-10 with 0 identifying no effect on work and 10 completely prevented from working. Overall work impairment due to ANS was calculated as 100 x Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]. Scores were calculated with the formula to derive the overall work impairment on each timepoints in percentage, and then changes of the percentage from baseline are reported.

    Time frame: Baseline and weeks 12 to 28

  41. Percentage of Participants in Each Category in Patients' Global Impression of Change (PGIC)

    The Patients' Global Impression of Change (PGIC) is a participant-rated instrument that measures change in participants overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 12 to 28

  42. Change From BL to Each Study Visit in Serum Hepcidin

    Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

    Time frame: Baseline and weeks 4,12,20,36,52,104

  43. Change From BL to Each Study Visit in Serum Ferritin

    Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104

  44. Change From BL to Each Study Visit in Serum Transferrin Saturation (TSAT)

    Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104

  45. Change From BL to Each Study Visit in Serum HbA1c Level

    HbA1c was measured at each timepoint and presented in 'fraction of 1' unit by dividing the values in percentage by 100, in order to fit for CDISC (Clinical Data Interchange Standards Consortium) standard terminology. Changes from baseline to each timepoint were reported in unit 'fraction of 1'. Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

    Time frame: Baseline and weeks 12, 28, 36, 44, 60, 84, 104

  46. Change From BL to Each Study Visit in Fasting Blood Glucose

    Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104

  47. Change From BL to Each Study Visit in Albumin/Creatinine Ratio in Urine

    Baseline assessment was the assessment from day 1 visit. If baseline value was missing, value from screening visit was used. In case of missing data, no imputation rules were applied. To compute the geometric mean of albumin/creatinine ratio in urine and associated 95% CI, the mean of log-transformed albumin/creatinine ratio in urine values (ratio) and associated 95% CI are back-transformed to the raw scale. All assessments collected after initiation of dialysis (acute or chronic) were excluded from the analysis.

    Time frame: Baseline and weeks 12, 24, 36, 52, 64, 76, 88, 104

  48. Change From BL to Each Study Visit in Serum Creatinine (Cr) Ratio

    Baseline assessment was the assessment from day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied. To compute the geometric mean of serum Cr (ratio) and associated 95% CI, the mean of log-transformed serum Cr (ratio) values and associated 95% CI are back-transformed to the raw scale. All assessments collected after initiation of dialysis (acute or chronic) were excluded from the analysis.

    Time frame: Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104

  49. Time to Doubling of Serum Creatinine or Chronic Dialysis or Renal Transplant Compared to Baseline

    The endpoint was defined as time to doubling serum creatinine or chronic dialysis or renal transplant what ever came first. Time to event was defined as (First event date - Analysis date of first dose intake + 1) / 365.25. First event date was defined as date of dialysis or date of renal transplant (whichever occurred first) and analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1 visit. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. The data evaluated until the safety emergent period, which was defined as the evaluation period from analysis date of first drug intake up to 28 days after the analysis last dose, and results were presented for every 6 months up to 2 years.

    Time frame: Baseline and year 0.5, year 1, year 1.5 and year 2

  50. Time to CKD Progression (Composite of Doubling Serum Creatinine, Chronic Dialysis or Renal Transplant, and Death)

    CKD progression was defined as date of occurrence of chronic dialysis or date of renal transplant or doubled serum creatinine or date of death, whichever came first. The time to CKD progression was calculated (in years) as (First event date - Analysis date of first dose intake + 1) / 365.25. First event date was defined as first occurrence of serum creatinine being doubled compared with baseline, first occurrence of chronic dialysis or renal transplant, occurrence of participants who died (whichever occurred first). Analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1 visit. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. The data evaluated until the safety emergent period, which was defined as the evaluation period from analysis date of first drug intake up to 28 days after the analysis last dose, and results were presented for every 6 months up to 2 years.

    Time frame: Baseline and year 0.5, year 1, year 1.5 and year 2

  51. Time to at Least 40% Decrease in eGFR From Baseline, Chronic Dialysis or Renal Transplant

    All eGFR values collected during the safety emergent period are considered, excluding those collected on or after initiation of dialysis (acute or chronic). The First event date was defined as First occurrence of 40% decrease in eGFR from baseline, first occurrence of chronic dialysis or renal transplant (whichever occurred first and Analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1 visit. The safety emergent period was defined as the evaluation period from the analysis date of first drug intake up to 28 days after the analysis date of last dose or end of study (EOS), whichever occurred first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. The data evaluated until the safety emergent period, which was defined as the evaluation period from analysis date of first drug intake up to 28 days after the analysis last dose, and results were presented for every 6 months up to 2 years.

    Time frame: Baseline and year 0.5, year 1, year 1.5 and year 2

07

Results

Posted Dec 17, 2020

Participant flow

Study population consisted of anemic participants with stages 3, 4 or 5 chronic kidney disease (CKD) (Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m\^2) who were not on dialysis. Participants were recruited from 125 study centers located in 22 countries.

Participant flow — Overall Study
MilestoneRoxadustatPlacebo
Started391203
Treatment received391203
Completed24589
Not completed146114
Withdrew: Death3916
Withdrew: Lack of efficacy326
Withdrew: Lost to follow-up51
Withdrew: Physician decision78
Withdrew: Protocol deviation30
Withdrew: Withdrawal by subject5852
Withdrew: Adverse event219
Withdrew: Non-compliance with study drug30
Withdrew: Miscellaneous62
Withdrew: Progressive disease10

Outcome measures

PrimaryPercentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response

Hemoglobin (Hb) response was measured as Yes or No. Response Yes (responders) was defined as: Hb ≥11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL, for participants with baseline Hb \> 8.0 g/dL; or Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at two consecutive visits with available data separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell (RBC) transfusion, erythropoiesis-stimulating agent (ESA), or intravenous (IV) iron prior to Hb response. This was the primary efficacy endpoint for EU (EMA).

Time frame:
Baseline to week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response
Percentage of ParticipantsRoxadustatPlacebo
Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response79.2 (74.8 to 83.1)9.9 (6.1 to 14.8)
Statistical analysis
  • Roxadustat vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 34.74 · 95% CI 20.48 to 58.93Please note Odds Ratio and CI are shown in percentages.
PrimaryHb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue Therapy

The change from baseline to the average Hb values across weeks 28 to 52 without having received rescue therapy. The Hb values from visit windows at weeks 28, 32, 36, 40, 44, 48 and 52 were used for the calculation of the average of weeks 28 to 52. This was the primary efficacy endpoint for US (FDA).

Time frame:
Baseline and weeks 28 to 52
Reported as:
Least squares mean · g/dL
Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue Therapy
g/dLRoxadustatPlacebo
Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue Therapy1.992 (1.82 to 2.16)0.300 (0.09 to 0.51)
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 1.692 · 95% CI 1.52 to 1.86
SecondaryHb Change From BL to the Average Hb in Weeks 28-36 Without Having Received Rescue Therapy Within 6 Weeks Prior to and During 8-Week Evaluation Period

The Hb values from visit windows at weeks 28, 32 and 36 were used for the calculation of the average of weeks 28 to 36.

Time frame:
Baseline and weeks 28 to 36
Reported as:
Least squares mean · g/dL
Hb Change From BL to the Average Hb in Weeks 28-36 Without Having Received Rescue Therapy Within 6 Weeks Prior to and During 8-Week Evaluation Period
g/dLRoxadustatPlacebo
Hb Change From BL to the Average Hb in Weeks 28-36 Without Having Received Rescue Therapy Within 6 Weeks Prior to and During 8-Week Evaluation Period2.069 (1.94 to 2.20)0.470 (0.30 to 0.64)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences. Tested using a fixed sequence testing procedure to maintain the overall two-sided type I error rate at 0.05.) · Least squares mean difference: 1.599 · 95% CI 1.41 to 1.78
SecondaryChange From BL in Low-Density Lipoprotein (LDL) Cholesterol (Regardless of Fasting Status) to the Average LDL Cholesterol of Weeks 12 to 28

Analysis was completed on all values collected on day 1 and weeks 12, 20 and 28.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Least squares mean · mmol/L
Change From BL in Low-Density Lipoprotein (LDL) Cholesterol (Regardless of Fasting Status) to the Average LDL Cholesterol of Weeks 12 to 28
mmol/LRoxadustatPlacebo
Change From BL in Low-Density Lipoprotein (LDL) Cholesterol (Regardless of Fasting Status) to the Average LDL Cholesterol of Weeks 12 to 28-0.650 (-0.76 to -0.54)0.051 (-0.08 to 0.18)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences. Tested using a fixed sequence testing procedure to maintain the overall two-sided type I error rate at 0.05.) · Least squares mean difference: -0.701 · 95% CI -0.83 to -0.57
SecondaryTime to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron)

The time to first use of rescue therapy was calculated (in years) as: (First event date - Analysis date of first dose intake + 1) / 365.25. The First event date was defined as Date of first dose of rescue medication during the efficacy emergent period and Analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1. The Efficacy Emergent Period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or the end of treatment (EOT) visit, whichever occurred first. Data reported was analysed by Kaplan-Meier estimate for cumulative proportion. Medication onset date was the date of the first use of rescue medication.

Time frame:
Baseline to week 104 (End of Treatment [EOT])
Reported as:
Number · Percentage of participants
Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron)
Percentage of participantsRoxadustatPlacebo
Year 0.56.1 (3.6 to 8.7)33.3 (26.5 to 40.1)
Year 113.0 (9.3 to 16.7)50.1 (42.4 to 57.7)
Year 1.522.0 (16.6 to 27.3)52.5 (44.5 to 60.5)
Year 226.3 (20.2 to 32.4)57.8 (48.7 to 66.9)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = <0.001 (Tested using a fixed sequence testing procedure to maintain the overall two-sided type I error rate at 0.05.) · Hazard ratio (hr): 0.238 · 95% CI 0.17 to 0.33
SecondaryChange From BL in Short Form (SF)-36 Vitality (VT) Sub-score to the Average VT Sub-score of Weeks 12 to 28

Change from BL in SF-36 VT sub-score to the average value in weeks 12-28 was calculated using the physical component scores (PCS) of SF-36. The multi-purpose, short-form health survey has 36 questions with an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. The survey measures eight dimensions or scales: (1) physical functioning (PF) (10 items); (2) role limitations due to physical health problems (RP) (3 items); (3) bodily pain (BP) (2 items); (4) social functioning (SF) (2 items); (5) general health perceptions (GH) (5 items); (6) role limitations due to emotional problems (RE) (3 items); (7) vitality, energy or fatigue (VT) (4 items); and (8) mental health (MH) (5 items). The SF-36 scores ranged from 0-100 with higher scores indicating better health status.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Least squares mean · Units on a Scale
Change From BL in Short Form (SF)-36 Vitality (VT) Sub-score to the Average VT Sub-score of Weeks 12 to 28
Units on a ScaleRoxadustatPlacebo
Change From BL in Short Form (SF)-36 Vitality (VT) Sub-score to the Average VT Sub-score of Weeks 12 to 282.788 (1.56 to 4.01)1.661 (0.23 to 3.10)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = =0.093 (LSM Difference p-value is for test of differences.Tested using a fixed sequence testing procedure to maintain the overall two-sided type I error rate at 0.05.) · Least squares mean difference: 1.127 · 95% CI -0.19 to 2.44
SecondaryChange From BL in SF-36 Physical Functioning (PF) Sub-score to the Average PF Sub-score of Weeks 12 to 28

Change from baseline in SF-36 PF normalized sub-score compared to the average PF sub-score of weeks 12 to 28. The multi-purpose, short-form health survey has 36 questions with an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Change from baseline in PF sub score of SF-36 to the average of weeks 12-28 was compared by treatment arm for all participants (primary analysis) and in the subsets of participants with baseline PF sub score below 35 and equal or above 35. The SF-36 scores ranged from 0-100 with higher scores indicating better health status. All available SF-36 PF values were used i.e., both scheduled and unscheduled for the calculation of the average PF sub-score of weeks 12 to 28.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Least squares mean · Units on a Scale
Change From BL in SF-36 Physical Functioning (PF) Sub-score to the Average PF Sub-score of Weeks 12 to 28
Units on a ScaleRoxadustatPlacebo
Change From BL in SF-36 Physical Functioning (PF) Sub-score to the Average PF Sub-score of Weeks 12 to 281.344 (0.15 to 2.54)0.632 (-0.76 to 2.03)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = =0.27 (LSM Difference p-value is for test of differences. Tested using a fixed sequence testing procedure to maintain the overall two-sided type I error rate at 0.05.) · Least squares mean difference: 0.713 · 95% CI -0.56 to 1.98
SecondaryChange From BL in Mean Arterial Pressure (MAP) to the Average MAP of Weeks 20 to 28

The MAP was derived for each visit from the average systolic (SBP) and diastolic blood pressure (DBP) calculated for each visit using the three readings and the following equation: MAP = (2/3) \* DBP + (1/3) \* SBP. Baseline assessment was the assessment on day 1 (average of the three readings). If the baseline assessment was missing, then the latest available value prior to first drug administration was used.

Time frame:
Baseline and weeks 20 to 28
Reported as:
Least squares mean · mmHg
Change From BL in Mean Arterial Pressure (MAP) to the Average MAP of Weeks 20 to 28
mmHgRoxadustatPlacebo
Change From BL in Mean Arterial Pressure (MAP) to the Average MAP of Weeks 20 to 28-0.814 (-1.83 to 0.20)-1.656 (-2.91 to -0.41)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = =0.182 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 0.842 · 95% CI -0.40 to 2.08
SecondaryTime to First Occurrence of Hypertension

Occurrence of hypertension was defined as SBP increase from BL ≥20 mmHg and SBP \>170 mmHg or DBP increase from BL ≥15 mmHg and DBP ≥110 mmHg. Time to first occurrence of hypertension was defined as first date where SBP criterion or DBP criterion is met, whichever occurred first. Data was analysed using Kaplan-Meier estimate for cumulative proportion.

Time frame:
Baseline and year 0.5, year 1, year 1.5 and year 2
Reported as:
Number · Percentage of participants
Time to First Occurrence of Hypertension
Percentage of participantsRoxadustatPlacebo
Year 0.511.4 (7.9 to 14.8)10.1 (5.5 to 14.7)
Year 114.8 (10.9 to 18.8)12.5 (7.3 to 17.7)
Year 1.517.5 (13.0 to 21.9)12.5 (7.3 to 17.7)
Year 218.5 (13.7 to 23.3)12.5 (7.3 to 17.7)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = =0.334 · Hazard ratio (hr): 1.290 · 95% CI 0.77 to 2.16
SecondaryRate of Progression of CKD Measured by Annualized Estimated Glomerular Filtration Rate (eGFR) Slope Over Time

Annualized eGFR slope over time was estimated by a random slopes and intercepts model using all available eGFR values (one baseline and all post-treatment values up to EOT period or start of dialysis adjusted on baseline Hb, region, CV history at baseline and the interaction terms (baseline eGFR by timepoint and baseline Hb by timepoint). All assessments collected after initiation of chronic dialysis (acute or chronic) are excluded from the analysis. Baseline assessment was the assessment from day 1 visit. If this value was missing, the value from screening visit was used.

Time frame:
Baseline to week 108
Reported as:
Least squares mean · ml/min per 1.73 m^2 per year
Rate of Progression of CKD Measured by Annualized Estimated Glomerular Filtration Rate (eGFR) Slope Over Time
ml/min per 1.73 m^2 per yearRoxadustatPlacebo
Rate of Progression of CKD Measured by Annualized Estimated Glomerular Filtration Rate (eGFR) Slope Over Time-2.65 (-3.29 to -2.02)-3.24 (-4.21 to -2.28)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = =0.316 · Least squares mean difference: 0.59 · 95% CI -0.57 to 1.75
SecondaryAverage Level of Hb Over Weeks 28 to 36 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period

All scheduled and unscheduled hemoglobin values from weeks 28 to 36 were taken into account for calculating the average values.

Time frame:
Weeks 28 to 36
Reported as:
Least squares mean · g/dL
Average Level of Hb Over Weeks 28 to 36 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period
g/dLRoxadustatPlacebo
Average Level of Hb Over Weeks 28 to 36 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period11.106 (10.97 to 11.24)9.468 (9.29 to 9.65)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences) · Least squares mean difference: 1.638 · 95% CI 1.44 to 1.84
SecondaryAverage Level of Hb Over Weeks 44 to 52 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period

All scheduled and unscheduled hemoglobin values from weeks 44 to 52 were taken into account for calculating the average values.

Time frame:
Weeks 44 to 52
Reported as:
Least squares mean · g/dL
Average Level of Hb Over Weeks 44 to 52 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period
g/dLRoxadustatPlacebo
Average Level of Hb Over Weeks 44 to 52 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period10.984 (10.85 to 11.12)9.381 (9.19 to 9.58)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM difference p-value is for test of differences.) · Least squares mean difference: 1.604 · 95% CI 1.39 to 1.82
SecondaryAverage Level of Hb Over Weeks 96 to 104 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period

All scheduled and unscheduled hemoglobin values from weeks 96 to 104 were taken into account for calculating the average values.

Time frame:
Weeks 96 to 104
Reported as:
Least squares mean · g/dL
Average Level of Hb Over Weeks 96 to 104 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period
g/dLRoxadustatPlacebo
Average Level of Hb Over Weeks 96 to 104 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period10.816 (10.63 to 11.00)9.324 (9.01 to 9.64)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.492 · 95% CI 1.14 to 1.85
SecondaryTime to Achieve the First Hb Response Without Rescue Therapy, as Defined by Primary Endpoint

Hb response was measured as Yes or No; Yes was defined as Hb ≥11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL, for participants with baseline Hb \> 8.0 g/dL; or Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL. For a participant without rescue therapy before Hb response (defined in 1 primary outcome), the time to achieve Hb response was calculated (in weeks) as: (First event date - Analysis date of first dose intake + 1) / 7 where First event date was defined as First date of both values that met the criteria for response. Participants who discontinued or received rescue therapy prior to the first Hb response or before the second consecutive Hb value defined as a response were classified as non responders and were censored at week 24 or end of efficacy emergent period, whichever came first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

Time frame:
Baseline to week 24
Reported as:
Number · Percentage of participants
Time to Achieve the First Hb Response Without Rescue Therapy, as Defined by Primary Endpoint
Percentage of participantsRoxadustatPlacebo
Week 426.0 (21.6 to 30.4)3.5 (0.9 to 6.0)
Week 859.8 (54.7 to 64.9)6.2 (2.8 to 9.7)
Week 1683.4 (79.3 to 87.5)9.4 (5.1 to 13.7)
Week 2489.1 (85.5 to 92.6)11.6 (6.8 to 16.5)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 19.001 · 95% CI 11.98 to 30.15
SecondaryHb Change From BL to Each Post-Dosing Time Point

All scheduled and unscheduled hemoglobin values that belong to each visit window were taken into account using one value per analysis window. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).

Time frame:
Baseline (day 1) and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104
Reported as:
Least squares mean · g/dL
Hb Change From BL to Each Post-Dosing Time Point
g/dLRoxadustatPlacebo
Hb Change From BL to Week 10.390 (0.29 to 0.49)-0.006 (-0.12 to 0.11)
Hb Change From BL to Week 20.977 (0.87 to 1.08)0.039 (-0.09 to 0.17)
Hb Change From BL to Week 41.591 (1.47 to 1.71)0.119 (-0.04 to 0.27)
Hb Change From BL to Week 61.927 (1.79 to 2.06)0.100 (-0.07 to 0.27)
Hb Change From BL to Week 82.236 (2.10 to 2.37)0.178 (0.01 to 0.35)
Hb Change From BL to Week 102.129 (1.99 to 2.26)0.180 (0.01 to 0.35)
Hb Change From BL to Week 122.412 (2.28 to 2.55)0.322 (0.15 to 0.49)
Hb Change From BL to Week 142.214 (2.08 to 2.35)0.163 (0.00 to 0.33)
Hb Change From BL to Week 162.365 (2.23 to 2.50)0.378 (0.20 to 0.56)
Hb Change From BL to Week 182.087 (1.95 to 2.23)0.246 (0.06 to 0.43)
Hb Change From BL to Week 202.191 (2.04 to 2.34)0.367 (0.18 to 0.56)
Hb Change From BL to Week 221.873 (1.73 to 2.02)0.222 (0.03 to 0.41)
Hb Change From BL to Week 241.802 (1.66 to 1.95)0.355 (0.16 to 0.55)
Hb Change From BL to Week 281.996 (1.85 to 2.14)0.435 (0.24 to 0.63)
Hb Change From BL to Week 321.911 (1.77 to 2.05)0.324 (0.13 to 0.52)
Hb Change From BL to Week 362.100 (1.95 to 2.25)0.410 (0.21 to 0.61)
Hb Change From BL to Week 401.887 (1.74 to 2.03)0.241 (0.04 to 0.45)
Hb Change From BL to Week 441.977 (1.82 to 2.13)0.278 (0.06 to 0.49)
Hb Change From BL to Week 481.695 (1.54 to 1.85)0.249 (0.03 to 0.46)
Hb Change From BL to Week 521.939 (1.78 to 2.10)0.298 (0.07 to 0.52)
Hb Change From BL to Week 561.725 (1.56 to 1.88)0.085 (-0.16 to 0.33)
Hb Change From BL to Week 601.988 (1.81 to 2.16)0.354 (0.09 to 0.62)
Hb Change From BL to Week 641.637 (1.45 to 1.82)0.233 (-0.06 to 0.52)
Hb Change From BL to Week 681.913 (1.74 to 2.09)0.414 (0.13 to 0.70)
Hb Change From BL to Week 721.765 (1.58 to 1.95)0.328 (0.03 to 0.63)
Hb Change From BL to Week 761.859 (1.67 to 2.05)0.674 (0.36 to 0.99)
Hb Change From BL to Week 801.752 (1.57 to 1.93)0.308 (0.01 to 0.61)
Hb Change From BL to Week 841.854 (1.66 to 2.05)0.480 (0.14 to 0.82)
Hb Change From BL to Week 881.570 (1.38 to 1.76)0.399 (0.06 to 0.74)
Hb Change From BL to Week 921.800 (1.60 to 2.00)0.418 (0.06 to 0.78)
Hb Change From BL to Week 961.701 (1.49 to 1.91)0.139 (-0.23 to 0.51)
Hb Change From BL to Week 1001.763 (1.57 to 1.96)0.315 (-0.03 to 0.66)
Hb Change From BL to Week 1041.857 (1.64 to 2.08)0.511 (0.11 to 0.91)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 0.396 · 95% CI 0.29 to 0.50
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 0.938 · 95% CI 0.81 to 1.07
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.471 · 95% CI 1.30 to 1.64
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.827 · 95% CI 1.64 to 2.02
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 2.058 · 95% CI 1.87 to 2.25
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.949 · 95% CI 1.75 to 2.14
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 2.090 · 95% CI 1.90 to 2.28
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 2.051 · 95% CI 1.86 to 2.24
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.987 · 95% CI 1.79 to 2.19
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.841 · 95% CI 1.64 to 2.05
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.824 · 95% CI 1.61 to 2.04
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.651 · 95% CI 1.43 to 1.87
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.447 · 95% CI 1.23 to 1.67
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.561 · 95% CI 1.34 to 1.78
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.587 · 95% CI 1.37 to 1.81
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.690 · 95% CI 1.46 to 1.92
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.645 · 95% CI 1.41 to 1.88
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.699 · 95% CI 1.45 to 1.94
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.446 · 95% CI 1.20 to 1.69
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.641 · 95% CI 1.39 to 1.89
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.640 · 95% CI 1.37 to 1.91
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.634 · 95% CI 1.33 to 1.94
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.404 · 95% CI 1.08 to 1.73
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.499 · 95% CI 1.18 to 1.82
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.438 · 95% CI 1.10 to 1.78
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.185 · 95% CI 0.83 to 1.54
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.443 · 95% CI 1.11 to 1.78
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.374 · 95% CI 0.99 to 1.75
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.171 · 95% CI 0.79 to 1.55
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.382 · 95% CI 0.98 to 1.78
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.563 · 95% CI 1.15 to 1.97
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.448 · 95% CI 1.06 to 1.83
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.347 · 95% CI 0.90 to 1.79
SecondaryHb Change From BL to the Average Hb Value of Weeks 28-36 Regardless of the Use of Rescue Therapy

The Hb values from visit windows from weeks 28 to 36 were used for the calculation of the average regardless of rescue therapy. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dosing).

Time frame:
Baseline and weeks 28 to 36
Reported as:
Least squares mean · g/dL
Hb Change From BL to the Average Hb Value of Weeks 28-36 Regardless of the Use of Rescue Therapy
g/dLRoxadustatPlacebo
Hb Change From BL to the Average Hb Value of Weeks 28-36 Regardless of the Use of Rescue Therapy2.013 (1.88 to 2.15)0.399 (0.22 to 0.58)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM difference p-value is for test of differences.) · Least squares mean difference: 1.614 · 95% CI 1.42 to 1.81
SecondaryHb Change From BL to the Average Hb Value of Weeks 44-52 Regardless of the Use of Rescue Therapy

The Hb values from visit windows from weeks 44 to 52 were used for the calculation of the average regardless of rescue therapy. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dosing).

Time frame:
Baseline and weeks 44 to 52
Reported as:
Least squares mean · g/dL
Hb Change From BL to the Average Hb Value of Weeks 44-52 Regardless of the Use of Rescue Therapy
g/dLRoxadustatPlacebo
Hb Change From BL to the Average Hb Value of Weeks 44-52 Regardless of the Use of Rescue Therapy1.886 (1.75 to 2.03)0.292 (0.10 to 0.48)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 1.594 · 95% CI 1.38 to 1.81
SecondaryHb Change From BL to the Average Hb Value of Weeks 96-104 Regardless of the Use of Rescue Therapy

The Hb values from visit windows from weeks 96 to 104 were used for the calculation of the average regardless of rescue therapy. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dosing).

Time frame:
Baseline and weeks 96 to 104
Reported as:
Least squares mean · g/dL
Hb Change From BL to the Average Hb Value of Weeks 96-104 Regardless of the Use of Rescue Therapy
g/dLRoxadustatPlacebo
Hb Change From BL to the Average Hb Value of Weeks 96-104 Regardless of the Use of Rescue Therapy1.779 (1.60 to 1.96)0.327 (0.01 to 0.64)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.001 (LSM difference p-value is for test of differences.) · Least squares mean difference: 1.452 · 95% CI 1.10 to 1.80
SecondaryPercentage of Hb Values Within 10.0-12.0 g/dL in Weeks 28-36 Without Use of Rescue Therapy

The percentage of Hb values measured during weeks 28-36 within 10.0 -12.0 g/dL, without having received rescue therapy within 6 weeks prior to and during the 8-week evaluation period is reported.

Time frame:
Baseline and weeks 28 to 36
Reported as:
Mean · Percentage of Hb values
Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 28-36 Without Use of Rescue Therapy
Percentage of Hb valuesRoxadustatPlacebo
Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 28-36 Without Use of Rescue Therapy64.18 ± 32.9034.20 ± 39.47
SecondaryPercentage of Hb Values Within 10.0-12.0 g/dL in Weeks 44-52 Without Use of Rescue Therapy

The percentage of Hb values measured during weeks 44-52 with values within 10.0 - 12.0 g/dL, without having received rescue therapy within 6 weeks prior to and during the 8-week evaluation period is reported.

Time frame:
Baseline and weeks 44 to 52
Reported as:
Mean · Percentage of Hb values
Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 44-52 Without Use of Rescue Therapy
Percentage of Hb valuesRoxadustatPlacebo
Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 44-52 Without Use of Rescue Therapy69.39 ± 32.4735.45 ± 41.75
SecondaryPercentage of Hb Values Within 10.0-12.0 g/dL in Weeks 96-104 Without Use of Rescue Therapy

The percentage of Hb values measured during weeks 96-104 within 10.0 -12.0 g/dL, without having received rescue therapy within 6 weeks prior to and during the 8-week evaluation period is reported.

Time frame:
Baseline and weeks 96 to 104
Reported as:
Mean · Percentage of Hb values
Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 96-104 Without Use of Rescue Therapy
Percentage of Hb valuesRoxadustatPlacebo
Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 96-104 Without Use of Rescue Therapy64.65 ± 37.1640.63 ± 44.39
SecondaryTime to First Hospitalization

Time to first hospitalization was defined in years as the First event date during the Efficacy Emergent Period - (Analysis date of first dose intake +1)/365.25. The first event date was defined as the Date of first admission. The Efficacy Emergent Period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. Analysis date of first dose intake was defined as the date of first study drug intake collected on day 1 visit. For participants who experienced more than one hospitalization, only their first event following study treatment was used. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

Time frame:
Baseline to week 104
Reported as:
Number · Percentage of participants
Time to First Hospitalization
Percentage of participantsRoxadustatPlacebo
Year 0.532.2 (27.3 to 37.0)39.8 (32.7 to 46.9)
Year 149.9 (44.6 to 55.2)49.3 (41.8 to 56.8)
Year 1.562.1 (56.3 to 67.9)64.0 (54.5 to 73.4)
Year 2NA (NA to NA)67.8 (57.9 to 77.7)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = =0.643 · Hazard ratio (hr): 0.945 · 95% CI 0.74 to 1.20
SecondaryNumber of Days of Hospitalization Per Patient Exposure Year (PEY)

The sum of the durations of all hospitalizations in days was adjusted for the duration of exposure. Derived only for participants with at least one hospitalization. The number of days of hospitalization per PEY was calculated as the sum of the durations of all hospitalizations in days \[Minimum (Date of discharge, End of Efficacy Emergent Period) - Date of admission + 1\] / \[Duration of Efficacy Emergent Period in days / 365.25\]. Participants can have more than one hospitalization.

Time frame:
Baseline to week 104
Reported as:
Mean · Number of days per PEY
Number of Days of Hospitalization Per Patient Exposure Year (PEY)
Number of days per PEYRoxadustatPlacebo
Number of Days of Hospitalization Per Patient Exposure Year (PEY)14.567 ± 29.21415.885 ± 30.224
SecondaryTime to First Use of Rescue Therapy (Composite of RBC, Transfusions, ESA Use, and IV Iron) in the First 24 Weeks of Treatment

Time to first use of rescue therapy in years. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

Time frame:
Baseline to week 24
Reported as:
Number · Percentage of participants
Time to First Use of Rescue Therapy (Composite of RBC, Transfusions, ESA Use, and IV Iron) in the First 24 Weeks of Treatment
Percentage of participantsRoxadustatPlacebo
Week 60.8 (0.0 to 1.7)6.0 (2.7 to 9.3)
Week 122.5 (0.9 to 4.1)15.8 (10.7 to 20.9)
Week 183.3 (1.5 to 5.2)25.3 (19.2 to 31.5)
Week 245.5 (3.1 to 7.9)32.1 (25.4 to 38.7)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.139 · 95% CI 0.08 to 0.23
SecondaryTime to First Use of RBC Transfusions

Time to First Use of RBC Transfusions during efficacy emergent period. For participants who have experienced more than one RBC transfusion, only their first event following study treatment was used. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

Time frame:
Baseline to week 104
Reported as:
Number · Percentage of participants
Time to First Use of RBC Transfusions
Percentage of participantsRoxadustatPlacebo
Year 0.52.9 (1.1 to 4.7)15.2 (10.1 to 20.4)
Year 15.6 (3.0 to 8.1)20.2 (14.2 to 26.2)
Year 1.512.1 (7.7 to 16.5)21.8 (15.1 to 28.5)
Year 215.0 (9.9 to 20.1)27.0 (17.7 to 36.4)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = <0.001 · Cox proportional hazard: 0.343 · 95% CI 0.21 to 0.55
SecondaryMean Monthly Number of RBC Packs

During efficacy emergent period, the mean monthly number of RBC packs was calculated as the sum of units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. In case of missing number of packs, values were estimated based on 1 unit for packed cells = 250 mL or 1 unit for whole blood = 500 mL. Participants without RBC transfusion were included with a value of zero. No estimation if values were missing.

Time frame:
Baseline to week 104
Reported as:
Mean · RBC Packs per 28 days
Mean Monthly Number of RBC Packs
RBC Packs per 28 daysRoxadustatPlacebo
Mean Monthly Number of RBC Packs0.041 ± 0.3970.089 ± 0.243
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = =0.128 · Least squares mean difference: -0.045 · 95% CI -0.10 to 0.01
SecondaryMean Monthly Volume of Blood Transfused

During efficacy emergent period, the mean monthly volume of blood transfused was calculated as the sum of blood volume transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occurred first. The mean monthly volume transfused was calculated as the sum of the volume transfused between the first dose and up to the last dose in the period divided by duration (in days) and multiplied by 28 days. Participants without RBC transfusion were included with a value of zero.

Time frame:
Baseline to week 104
Reported as:
Mean · Milliliters (ml) per 28 days
Mean Monthly Volume of Blood Transfused
Milliliters (ml) per 28 daysRoxadustatPlacebo
Mean Monthly Volume of Blood Transfused11.331 ± 106.62422.596 ± 60.666
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = =0.183 · Least squares mean difference: -10.429 · 95% CI -25.81 to 4.95
SecondaryTime to First Use of ESA Rescue Therapy

Time to First Use of ESA Rescue Therapy during efficacy emergent period. For participants with use of ESA, the time to first use of ESA was calculated as (First event date - Analysis date of first dose intake + 1) / 365.25. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occured first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. Participants without ESA rescue were censored at the end of treatment.

Time frame:
Baseline to week 104
Reported as:
Number · Percentage of participants
Time to First Use of ESA Rescue Therapy
Percentage of participantsRoxadustatPlacebo
Year 0.51.8 (0.4 to 3.2)20.4 (14.5 to 26.3)
Year 14.8 (2.4 to 7.2)36.4 (28.9 to 43.9)
Year 1.56.0 (3.1 to 8.9)42.3 (33.9 to 50.8)
Year 26.7 (3.5 to 9.9)42.3 (33.9 to 50.8)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.101 · 95% CI 0.06 to 0.17
SecondaryTime to First Use of IV Iron

Time to first use of IV iron during efficacy emergent period in years. For participants with use of IV iron, the time to first use of IV iron was calculated as (First event date - Analysis date of first dose intake + 1) / 365.25. The efficacy emergent period was defined as the evaluation period from the analysis date of first dose intake up to 7 days after the analysis date of last dose or EOT visit, whichever occurred first.Data analysis was completed using Kaplan-Meier estimate for cumulative proportion.

Time frame:
Baseline to week 104
Reported as:
Number · Percentage of participants
Time to First Use of IV Iron
Percentage of participantsRoxadustatPlacebo
Year 0.52.3 (0.7 to 3.9)6.2 (2.7 to 9.8)
Year 15.3 (2.8 to 7.8)9.4 (4.8 to 14.0)
Year 1.57.5 (4.3 to 10.7)10.7 (5.5 to 15.9)
Year 210.6 (6.3 to 14.8)19.1 (8.8 to 29.5)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = =0.045 · Hazard ratio (hr): 0.538 · 95% CI 0.29 to 0.99
SecondaryChange From BL to Each Post-Dosing Visit in Total Cholesterol

Change from baseline to each planned assessment for total cholesterol is reported. Baseline was defined as the value on day 1. If the value was missing, the latest value prior to first study drug administration was used.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104
Reported as:
Mean · mmol/L
Change From BL to Each Post-Dosing Visit in Total Cholesterol
mmol/LRoxadustatPlacebo
Week 4-1.151 ± 1.0580.108 ± 0.842
Week 8-1.066 ± 1.0860.048 ± 0.932
Week 12-0.836 ± 1.1730.088 ± 1.116
Week 20-0.747 ± 1.2270.193 ± 1.129
Week 28-0.816 ± 1.2840.201 ± 1.271
Week 36-0.803 ± 1.3000.183 ± 1.174
Week 44-0.854 ± 1.2380.077 ± 1.346
Week 52-0.815 ± 1.3140.104 ± 1.304
Week 68-0.971 ± 1.3820.188 ± 1.222
Week 84-1.055 ± 1.5540.102 ± 1.284
Week 104-0.944 ± 1.5840.218 ± 1.067
SecondaryChange From BL to Each Post-Dosing Visit in Low Density Lipoprotein (LDL)/High-Density Lipoprotein (HDL) Ratio

Change from baseline to each planned assessment for LDL/HDL ratio is reported. Baseline was defined as the value on Day 1. If this value was missing, the latest value prior to first study drug administration was used.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104
Reported as:
Mean · Ratio
Change From BL to Each Post-Dosing Visit in Low Density Lipoprotein (LDL)/High-Density Lipoprotein (HDL) Ratio
RatioRoxadustatPlacebo
Week 4-0.331 ± 0.7770.076 ± 0.635
Week 8-0.374 ± 0.9520.068 ± 0.685
Week 12-0.268 ± 0.9050.081 ± 0.915
Week 20-0.250 ± 1.0240.155 ± 0.788
Week 28-0.313 ± 1.0570.156 ± 0.861
Week 36-0.349 ± 1.0400.157 ± 1.053
Week 44-0.368 ± 1.0990.099 ± 1.198
Week 52-0.429 ± 1.1250.019 ± 1.076
Week 68-0.466 ± 1.2190.052 ± 0.955
Week 84-0.509 ± 1.3070.114 ± 1.113
Week 104-0.414 ± 1.3060.105 ± 0.873
SecondaryChange From BL to Each Post-Dosing Visit in Non-HDL Cholesterol

Change from baseline to each planned assessment for non-HDL is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104
Reported as:
Mean · mmol/L
Change From BL to Each Post-Dosing Visit in Non-HDL Cholesterol
mmol/LRoxadustatPlacebo
Week 4-0.969 ± 0.9890.118 ± 0.789
Week 8-0.909 ± 1.0640.070 ± 0.864
Week 12-0.709 ± 1.1070.078 ± 1.050
Week 20-0.638 ± 1.1750.186 ± 1.072
Week 28-0.710 ± 1.2270.206 ± 1.227
Week 36-0.711 ± 1.2390.202 ± 1.133
Week 44-0.751 ± 1.1900.106 ± 1.342
Week 52-0.751 ± 1.2760.104 ± 1.299
Week 68-0.882 ± 1.3250.174 ± 1.187
Week 84-0.939 ± 1.5180.089 ± 1.343
Week 104-0.839 ± 1.5540.174 ± 1.014
SecondaryChange From BL to Each Post-Dosing Visit in Apolipoproteins A1 (ApoA1)

Change from baseline to each planned assessment for apolipoproteins A1 is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104
Reported as:
Mean · g/L
Change From BL to Each Post-Dosing Visit in Apolipoproteins A1 (ApoA1)
g/LRoxadustatPlacebo
Week 4-0.168 ± 0.2320.013 ± 0.190
Week 8-0.148 ± 0.2290.008 ± 0.227
Week 12-0.131 ± 0.2540.004 ± 0.203
Week 20-0.114 ± 0.2450.036 ± 0.222
Week 28-0.104 ± 0.2650.006 ± 0.233
Week 36-0.101 ± 0.2520.002 ± 0.223
Week 44-0.135 ± 0.259-0.013 ± 0.268
Week 52-0.090 ± 0.260-0.028 ± 0.248
Week 68-0.157 ± 0.3100.018 ± 0.204
Week 84-0.132 ± 0.2820.060 ± 0.196
Week 104-0.098 ± 0.2270.070 ± 0.136
SecondaryChange From BL to Each Post-Dosing Visit in Apolipoproteins B (ApoB)

Change from baseline to each planned assessment for apolipoproteins B is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104
Reported as:
Mean · mg/dL
Change From BL to Each Post-Dosing Visit in Apolipoproteins B (ApoB)
mg/dLRoxadustatPlacebo
Week 4-19.891 ± 20.6692.059 ± 22.220
Week 8-19.483 ± 21.0092.059 ± 20.297
Week 12-14.935 ± 24.6130.278 ± 21.707
Week 20-12.709 ± 24.4245.711 ± 25.883
Week 28-13.782 ± 28.6349.746 ± 26.864
Week 36-14.866 ± 25.4696.623 ± 25.895
Week 44-15.593 ± 26.5943.222 ± 30.771
Week 52-14.122 ± 27.5034.676 ± 31.440
Week 68-18.746 ± 28.6332.786 ± 28.900
Week 84-20.133 ± 28.13412.500 ± 32.152
Week 104-10.917 ± 22.88514.750 ± 20.271
SecondaryChange From BL to Each Post-Dosing Visit in Ratio ApoB/ApoA1

Change from baseline to each planned assessment for ratio of ApoB/ApoA1 is reported. Baseline was defined as the value on day 1. If this value was missing, the latest value prior to first study drug administration was used.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 68, 84, 104
Reported as:
Mean · Ratio
Change From BL to Each Post-Dosing Visit in Ratio ApoB/ApoA1
RatioRoxadustatPlacebo
Week 4-0.073 ± 0.1650.010 ± 0.169
Week 8-0.084 ± 0.2020.000 ± 0.184
Week 12-0.059 ± 0.164-0.006 ± 0.201
Week 20-0.043 ± 0.1890.009 ± 0.198
Week 28-0.066 ± 0.2220.063 ± 0.205
Week 36-0.070 ± 0.2000.045 ± 0.213
Week 44-0.053 ± 0.2200.031 ± 0.265
Week 52-0.065 ± 0.2070.047 ± 0.266
Week 68-0.086 ± 0.2120.001 ± 0.184
Week 84-0.066 ± 0.2100.058 ± 0.295
Week 104-0.024 ± 0.1260.085 ± 0.132
SecondaryPercentage of Participants With Mean LDL Cholesterol <100 mg/dL Calculated Over Weeks 12 to 28

Mean LDL cholesterol \<100 mg/dL over weeks 12 to 28 was defined as a binary variable (Yes/No), where Yes was defined as mean LDL cholesterol \<100 mg/dL over weeks 12 to 28. Participants without any LDL value within this duration were excluded.

Time frame:
Weeks 12 to 28
Reported as:
Number · Percentage of Participants
Percentage of Participants With Mean LDL Cholesterol <100 mg/dL Calculated Over Weeks 12 to 28
Percentage of ParticipantsRoxadustatPlacebo
Yes (Regardless of fasting status)62.941.1
No (Regardless of fasting status)37.158.9
SecondaryPercentage of Participants Who Have Achieved Antihypertensive Treatment Goal in CKD Participants Over Weeks 12-28

Occurrence of achieved antihypertensive treatment goal was defined as the average SBP \< 130 mmHg and the average DBP \< 80 mmHg over the period of weeks 12-28. Participants without any blood pressure measurement were excluded.

Time frame:
Weeks 12 to 28
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Have Achieved Antihypertensive Treatment Goal in CKD Participants Over Weeks 12-28
Percentage of ParticipantsRoxadustatPlacebo
Yes25.628.0
No74.472.0
SecondaryChange From BL to the Average Value of Weeks 12-28 in Quality of Life (QoL) SF-36 Physical Component Score (PCS)

The 36-Item short-form health survey (SF-36) is a multi-purpose survey with 36 questions. It provides an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. For each scale scores range from 0-100. The physical component score was calculated based on the results of the SF-36 scores. Higher scores indicate better health status.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Least squares mean · Units on a Scale
Change From BL to the Average Value of Weeks 12-28 in Quality of Life (QoL) SF-36 Physical Component Score (PCS)
Units on a ScaleRoxadustatPlacebo
Change From BL to the Average Value of Weeks 12-28 in Quality of Life (QoL) SF-36 Physical Component Score (PCS)1.842 (0.88 to 2.80)1.468 (0.34 to 2.59)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = =0.475 (LSM Difference p-value is for test of differences.) · Least squares mean difference: 0.374 · 95% CI -0.65 to 1.40
SecondaryChange From BL to the Average Value of Weeks 12-28 in Anemia Subscale (Ans) of Functional Assessment of Cancer Therapy (FACT-An) Score

Baseline FACT-An AnS was defined as the FACT-An AnS value on Day 1. Together with the Functional Assessment of Cancer Therapy - General (FACT-G), the Anemia Subscale (AnS) is referred to as the FACT-An Total. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The Anemia AnS score range is 0 to 80. For the above score, a higher score indicates better QoL.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Least squares mean · Units on a Scale
Change From BL to the Average Value of Weeks 12-28 in Anemia Subscale (Ans) of Functional Assessment of Cancer Therapy (FACT-An) Score
Units on a ScaleRoxadustatPlacebo
Change From BL to the Average Value of Weeks 12-28 in Anemia Subscale (Ans) of Functional Assessment of Cancer Therapy (FACT-An) Score4.470 (2.86 to 6.08)2.766 (0.91 to 4.62)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = =0.047 (LSM difference p-value is for test of differences) · Least squares mean difference: 1.704 · 95% CI 0.02 to 3.38
SecondaryChange From BL to the Average Value of Weeks 12-28 in Total FACT-An Score

Baseline FACT-An Total Score was defined as the FACT-An Total score on Day 1. Total Fact-An score is composed of FACT-G and Ans scales. FACT-G contains 27 items that cover four dimensions of well-being: physical (PWB) - 7 items, functional (FWB) - 7 items, social/family (SWB) - 7 items, and emotional (EWB) - 6 items. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The total score is obtained by summation of the scores from PWB, SWB, EWB, FWB and AnS. The FACT-An Total Score scale range is 0-188. A higher score indicates better QoL.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Least squares mean · Units on a Scale
Change From BL to the Average Value of Weeks 12-28 in Total FACT-An Score
Units on a ScaleRoxadustatPlacebo
Change From BL to the Average Value of Weeks 12-28 in Total FACT-An Score5.777 (2.60 to 8.95)3.691 (0.01 to 7.37)
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = =0.225 · Least squares mean difference: 2.086 · 95% CI -1.29 to 5.46
SecondaryChange From BL to the Average Value of Weeks 12-28 in the Euroqol Questionnaire - 5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score

The Euroqol Questionnaire - 5 Dimensions 5 Levels (EQ-5D 5L) is a self-reported questionnaire. The EQ-5D 5L is used as a measure of respondents' Health Related Quality of Life (HRQoL). The EQ-5D 5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D 5L descriptive system comprises of 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, extreme problems. The VAS records the respondent's self-rated health status on a graduated (0-100) scale, where the answers are labeled 'Best imaginable health state' and 'Worst imaginable health state' with higher scores for higher HRQoL.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Mean · Units on a Scale
Change From BL to the Average Value of Weeks 12-28 in the Euroqol Questionnaire - 5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score
Units on a ScaleRoxadustatPlacebo
Change From BL to the Average Value of Weeks 12-28 in the Euroqol Questionnaire - 5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score5.390 ± 17.2780.990 ± 15.859
SecondaryChange From BL to the Average Value of Weeks 12-28 in Overall Work Impairment Due to Anaemic Symptoms

Work productivity and activity impairment: anemic symptoms (WPAI:ANS) questionnaire version 2 was used to measure work and activity impairment during the last seven days due to anemia. It is self-assessed questionnaire which consists of 6 questions covering work and daily activities. Questions include asking if participant is working, how many hours the person missed work due to anemic symptoms, how many hours the person missed work due to other reasons, how many hours participant actually worked and how the anemic symptoms impacted their productivity and ability to do daily activities. For the last 2 questions, they were scored from 0-10 with 0 identifying no effect on work and 10 completely prevented from working. Overall work impairment due to ANS was calculated as 100 x Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]. Scores were calculated with the formula to derive the overall work impairment on each timepoints in percentage, and then changes of the percentage from baseline are reported.

Time frame:
Baseline and weeks 12 to 28
Reported as:
Mean · Percentage of work impairment
Change From BL to the Average Value of Weeks 12-28 in Overall Work Impairment Due to Anaemic Symptoms
Percentage of work impairmentRoxadustatPlacebo
Change From BL to the Average Value of Weeks 12-28 in Overall Work Impairment Due to Anaemic Symptoms-5.965 ± 21.856-4.230 ± 23.679
SecondaryPercentage of Participants in Each Category in Patients' Global Impression of Change (PGIC)

The Patients' Global Impression of Change (PGIC) is a participant-rated instrument that measures change in participants overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 12 to 28
Reported as:
Number · Percentage of Participants
Percentage of Participants in Each Category in Patients' Global Impression of Change (PGIC)
Percentage of ParticipantsRoxadustatPlacebo
Week 12 [Very much improved + Much improved]41.218.9
Week 28 [Very much improved + Much improved]46.428.6
SecondaryChange From BL to Each Study Visit in Serum Hepcidin

Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

Time frame:
Baseline and weeks 4,12,20,36,52,104
Reported as:
Mean · ug/L
Change From BL to Each Study Visit in Serum Hepcidin
ug/LRoxadustatPlacebo
Week 4-19.835 ± 29.7651.748 ± 35.368
Week 12-17.369 ± 31.5720.971 ± 33.952
Week 20-10.684 ± 35.858-1.879 ± 30.661
Week 36-12.981 ± 32.3510.803 ± 39.816
Week 52-12.274 ± 37.4452.025 ± 40.678
Week 104-10.051 ± 33.671-7.436 ± 22.923
SecondaryChange From BL to Each Study Visit in Serum Ferritin

Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104
Reported as:
Mean · pmol/L
Change From BL to Each Study Visit in Serum Ferritin
pmol/LRoxadustatPlacebo
Week 4-221.827 ± 248.90211.564 ± 335.096
Week 8-247.955 ± 295.9201.789 ± 309.673
Week 12-265.812 ± 318.433-21.098 ± 254.782
Week 20-198.349 ± 284.015-32.561 ± 320.382
Week 28-184.501 ± 341.114-5.123 ± 470.691
Week 36-142.876 ± 608.67736.005 ± 538.357
Week 44-137.151 ± 352.71557.373 ± 594.125
Week 52164.009 ± 564.39693.245 ± 640.998
Week 60-133.499 ± 467.931-18.833 ± 441.131
Week 68-159.906 ± 453.80239.794 ± 581.616
Week 76-149.226 ± 408.12625.291 ± 627.834
Week 84-103.284 ± 530.02193.647 ± 753.265
Week 92-106.070 ± 464.1921.011 ± 474.434
Week 100-119.647 ± 452.20930.829 ± 514.823
Week 104-107.814 ± 458.7024.524 ± 475.524
SecondaryChange From BL to Each Study Visit in Serum Transferrin Saturation (TSAT)

Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104
Reported as:
Mean · Percentage saturated
Change From BL to Each Study Visit in Serum Transferrin Saturation (TSAT)
Percentage saturatedRoxadustatPlacebo
Week 4-7.4 ± 11.70.7 ± 11.4
Week 8-5.7 ± 11.7-0.4 ± 13.0
Week 12-4.6 ± 13.5-0.7 ± 11.5
Week 20-1.1 ± 13.4-0.3 ± 11.5
Week 28-1.8 ± 13.80.8 ± 13.2
Week 36-1.6 ± 13.61.1 ± 14.6
Week 44-0.2 ± 14.01.0 ± 16.0
Week 52-0.7 ± 13.60.0 ± 16.3
Week 60-0.6 ± 14.1-2.7 ± 13.9
Week 68-2.2 ± 13.1-3.3 ± 12.3
Week 76-2.6 ± 13.8-1.7 ± 13.9
Week 84-3.4 ± 13.3-3.6 ± 13.8
Week 92-1.9 ± 13.2-1.8 ± 12.8
Week 1000.0 ± 13.40.7 ± 12.0
Week 104-0.4 ± 12.60.0 ± 12.3
SecondaryChange From BL to Each Study Visit in Serum HbA1c Level

HbA1c was measured at each timepoint and presented in 'fraction of 1' unit by dividing the values in percentage by 100, in order to fit for CDISC (Clinical Data Interchange Standards Consortium) standard terminology. Changes from baseline to each timepoint were reported in unit 'fraction of 1'. Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

Time frame:
Baseline and weeks 12, 28, 36, 44, 60, 84, 104
Reported as:
Mean · Fraction of 1
Change From BL to Each Study Visit in Serum HbA1c Level
Fraction of 1RoxadustatPlacebo
Week 120.0007 ± 0.0064-0.0001 ± 0.0061
Week 280.0006 ± 0.00860.0008 ± 0.0091
Week 360.0011 ± 0.00980.0007 ± 0.0075
Week 440.0018 ± 0.0081-0.0002 ± 0.0074
Week 600.0009 ± 0.00730.0012 ± 0.0080
Week 840.0028 ± 0.00850.0022 ± 0.0111
Week 1040.0014 ± 0.00730.0004 ± 0.0059
SecondaryChange From BL to Each Study Visit in Fasting Blood Glucose

Baseline was assessed on Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104
Reported as:
Mean · mmol/L
Change From BL to Each Study Visit in Fasting Blood Glucose
mmol/LRoxadustatPlacebo
Week 40.107 ± 2.573-0.076 ± 2.730
Week 8-0.103 ± 3.179-0.162 ± 3.118
Week 12-0.100 ± 3.504-0.153 ± 4.629
Week 20-0.302 ± 4.0520.523 ± 2.981
Week 280.160 ± 3.4890.045 ± 3.281
Week 360.015 ± 2.991-0.117 ± 2.812
Week 440.073 ± 2.6830.801 ± 3.416
Week 520.048 ± 4.348-0.086 ± 4.883
Week 600.130 ± 2.9071.190 ± 3.946
Week 680.185 ± 2.8310.698 ± 3.386
Week 76-0.015 ± 2.031-0.671 ± 5.148
Week 840.495 ± 3.1170.435 ± 2.037
Week 920.612 ± 2.494-0.861 ± 3.298
Week 1000.405 ± 2.932-0.699 ± 2.161
Week 1040.125 ± 2.6330.237 ± 3.938
SecondaryChange From BL to Each Study Visit in Albumin/Creatinine Ratio in Urine

Baseline assessment was the assessment from day 1 visit. If baseline value was missing, value from screening visit was used. In case of missing data, no imputation rules were applied. To compute the geometric mean of albumin/creatinine ratio in urine and associated 95% CI, the mean of log-transformed albumin/creatinine ratio in urine values (ratio) and associated 95% CI are back-transformed to the raw scale. All assessments collected after initiation of dialysis (acute or chronic) were excluded from the analysis.

Time frame:
Baseline and weeks 12, 24, 36, 52, 64, 76, 88, 104
Reported as:
Geometric mean · Ratio
Change From BL to Each Study Visit in Albumin/Creatinine Ratio in Urine
RatioRoxadustatPlacebo
Week 121.08 (0.96 to 1.20)1.06 (0.84 to 1.34)
Week 241.19 (1.04 to 1.36)1.16 (0.89 to 1.53)
Week 361.21 (1.04 to 1.41)1.04 (0.77 to 1.40)
Week 521.28 (1.02 to 1.59)1.04 (0.72 to 1.51)
Week 641.25 (0.84 to 1.87)0.96 (0.53 to 1.71)
Week 761.12 (0.51 to 2.44)0.82 (0.41 to 1.65)
Week 881.10 (0.38 to 3.17)0.51 (0.27 to 0.97)
Week 1041.92 (0.75 to 4.89)0.38 (0.08 to 1.88)
SecondaryChange From BL to Each Study Visit in Serum Creatinine (Cr) Ratio

Baseline assessment was the assessment from day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied. To compute the geometric mean of serum Cr (ratio) and associated 95% CI, the mean of log-transformed serum Cr (ratio) values and associated 95% CI are back-transformed to the raw scale. All assessments collected after initiation of dialysis (acute or chronic) were excluded from the analysis.

Time frame:
Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104
Reported as:
Geometric mean · Ratio
Change From BL to Each Study Visit in Serum Creatinine (Cr) Ratio
RatioRoxadustatPlacebo
Week 41.01 (1.00 to 1.03)1.05 (1.03 to 1.07)
Week 81.03 (1.01 to 1.05)1.07 (1.04 to 1.09)
Week 121.04 (1.02 to 1.06)1.07 (1.04 to 1.11)
Week 201.08 (1.06 to 1.12)1.09 (1.05 to 1.13)
Week 281.12 (1.08 to 1.16)1.13 (1.08 to 1.17)
Week 361.12 (1.08 to 1.16)1.12 (1.07 to 1.18)
Week 441.12 (1.07 to 1.16)1.16 (1.10 to 1.22)
Week 521.12 (1.07 to 1.16)1.15 (1.09 to 1.22)
Week 601.09 (1.05 to 1.14)1.15 (1.07 to 1.23)
Week 681.11 (1.06 to 1.17)1.24 (1.13 to 1.37)
Week 761.13 (1.07 to 1.20)1.23 (1.12 to 1.36)
Week 841.13 (1.07 to 1.20)1.19 (1.05 to 1.35)
Week 921.19 (1.12 to 1.27)1.22 (1.05 to 1.41)
Week 1001.16 (1.08 to 1.24)1.26 (1.06 to 1.50)
Week 1041.16 (1.05 to 1.27)1.28 (1.09 to 1.51)
SecondaryTime to Doubling of Serum Creatinine or Chronic Dialysis or Renal Transplant Compared to Baseline

The endpoint was defined as time to doubling serum creatinine or chronic dialysis or renal transplant what ever came first. Time to event was defined as (First event date - Analysis date of first dose intake + 1) / 365.25. First event date was defined as date of dialysis or date of renal transplant (whichever occurred first) and analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1 visit. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. The data evaluated until the safety emergent period, which was defined as the evaluation period from analysis date of first drug intake up to 28 days after the analysis last dose, and results were presented for every 6 months up to 2 years.

Time frame:
Baseline and year 0.5, year 1, year 1.5 and year 2
Reported as:
Number · Percentage of participants
Time to Doubling of Serum Creatinine or Chronic Dialysis or Renal Transplant Compared to Baseline
Percentage of participantsRoxadustatPlacebo
Years 0.517.4 (13.4 to 21.4)17.8 (12.3 to 23.4)
Years 136.8 (31.6 to 42.1)35.4 (27.9 to 42.9)
Years 1.547.3 (41.4 to 53.1)48.2 (38.6 to 57.8)
Years 255.0 (48.5 to 61.4)54.7 (43.8 to 65.6)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = =0.973 · Hazard ratio (hr): 0.995 · 95% CI 0.75 to 1.32
SecondaryTime to CKD Progression (Composite of Doubling Serum Creatinine, Chronic Dialysis or Renal Transplant, and Death)

CKD progression was defined as date of occurrence of chronic dialysis or date of renal transplant or doubled serum creatinine or date of death, whichever came first. The time to CKD progression was calculated (in years) as (First event date - Analysis date of first dose intake + 1) / 365.25. First event date was defined as first occurrence of serum creatinine being doubled compared with baseline, first occurrence of chronic dialysis or renal transplant, occurrence of participants who died (whichever occurred first). Analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1 visit. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. The data evaluated until the safety emergent period, which was defined as the evaluation period from analysis date of first drug intake up to 28 days after the analysis last dose, and results were presented for every 6 months up to 2 years.

Time frame:
Baseline and year 0.5, year 1, year 1.5 and year 2
Reported as:
Number · Percentage of participants
Time to CKD Progression (Composite of Doubling Serum Creatinine, Chronic Dialysis or Renal Transplant, and Death)
Percentage of participantsRoxadustatPlacebo
Years 0.520.5 (16.3 to 24.7)20.0 (14.2 to 25.8)
Years 140.3 (35.1 to 45.5)38.3 (30.7 to 45.8)
Years 1.550.2 (44.5 to 55.9)50.5 (41.1 to 59.9)
Years 258.9 (52.7 to 65.1)61.1 (50.5 to 71.7)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = =0.972 · Hazard ratio (hr): 0.995 · 95% CI 0.76 to 1.30
SecondaryTime to at Least 40% Decrease in eGFR From Baseline, Chronic Dialysis or Renal Transplant

All eGFR values collected during the safety emergent period are considered, excluding those collected on or after initiation of dialysis (acute or chronic). The First event date was defined as First occurrence of 40% decrease in eGFR from baseline, first occurrence of chronic dialysis or renal transplant (whichever occurred first and Analysis date of first dose intake was defined as date of first study drug dose intake collected on day 1 visit. The safety emergent period was defined as the evaluation period from the analysis date of first drug intake up to 28 days after the analysis date of last dose or end of study (EOS), whichever occurred first. Data analysis was completed using Kaplan-Meier estimate for cumulative proportion. The data evaluated until the safety emergent period, which was defined as the evaluation period from analysis date of first drug intake up to 28 days after the analysis last dose, and results were presented for every 6 months up to 2 years.

Time frame:
Baseline and year 0.5, year 1, year 1.5 and year 2
Reported as:
Number · Percentage of participants
Time to at Least 40% Decrease in eGFR From Baseline, Chronic Dialysis or Renal Transplant
Percentage of participantsRoxadustatPlacebo
Years 0.520.7 (16.5 to 25.0)22.3 (16.2 to 28.4)
Years 144.4 (39.0 to 49.8)44.0 (36.2 to 51.7)
Years 1.554.6 (48.9 to 60.4)62.8 (53.2 to 72.5)
Years 264.5 (64.5 to 70.7)67.0 (56.8 to 77.1)
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = =0.439 · Hazard ratio (hr): 0.905 · 95% CI 0.70 to 1.16

Adverse events

Collected over From first dose of study drug up to 28 days after the last dose of study drug (up to 108 weeks), and up to 2.836 years at maximum for all-cause mortality. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat45/391 (11.5%)241/391 (61.6%)204/391 (52.2%)
Placebo20/203 (9.9%)115/203 (56.7%)103/203 (50.7%)
Most frequent serious events
Showing 10 of 233
Most frequent serious events
EventRoxadustatPlacebo
End stage renal diseaseRenal and urinary disorders135/39162/203
PneumoniaInfections and infestations17/39112/203
Glomerular filtration rate decreasedInvestigations21/39111/203
AzotaemiaRenal and urinary disorders10/3918/203
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications14/3910/203
AnaemiaBlood and lymphatic system disorders8/3917/203
Hypertensive crisisVascular disorders4/3915/203
Myocardial infarctionCardiac disorders8/3913/203
Acute myocardial infarctionCardiac disorders6/3912/203
SepsisInfections and infestations6/3910/203
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRoxadustatPlacebo
HypertensionVascular disorders85/39127/203
AnaemiaBlood and lymphatic system disorders16/39131/203
Oedema peripheralGeneral disorders44/39121/203
Viral upper respiratory tract infectionInfections and infestations38/3919/203
HyperkalaemiaMetabolism and nutrition disorders36/39113/203
NauseaGastrointestinal disorders34/3916/203
DiarrhoeaGastrointestinal disorders32/3916/203
Iron deficiencyMetabolism and nutrition disorders26/3918/203
Glomerular filtration rate decreasedInvestigations24/39113/203
AstheniaGeneral disorders18/39111/203

Baseline characteristics

The analysis population was the All Randomized, which consisted of participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Year)RoxadustatPlaceboTotal
Mean60.6 ± 13.561.7 ± 13.861.0 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)RoxadustatPlaceboTotal
Female222104326
Male16999268
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RoxadustatPlaceboTotal
American Indian or Alaska Native000
Asian909
Native Hawaiian or Other Pacific Islander000
Black or African American10313
White335182517
More than one race000
Unknown or Not Reported371855
History of Diabetes (Type 1 or 2)
History of Diabetes (Type 1 or 2)(Participants)RoxadustatPlaceboTotal
Yes14689235
No245114359
Iron Repletion at Baseline
Iron Repletion at Baseline(Participants)RoxadustatPlaceboTotal
TSAT >= 20% and Ferritin >= 100 ng/mL204109313
TSAT < 20% or Ferritin < 100 ng/mL18794281
Baseline Hemoglobin (Hb) Value
Baseline Hemoglobin (Hb) Value(g/dL)RoxadustatPlaceboTotal
Mean9.08 ± 0.769.10 ± 0.729.08 ± 0.75
Baseline Estimated Glomerular Filtration Rate (eGFR)
Baseline Estimated Glomerular Filtration Rate (eGFR)(mL/min/1.73m^2)RoxadustatPlaceboTotal
Mean16.5 ± 10.217.2 ± 11.716.7 ± 10.7
Time From Chronic Kidney Disease (CKD) Diagnosis
Time From Chronic Kidney Disease (CKD) Diagnosis(Years)RoxadustatPlaceboTotal
Mean5.65 ± 7.024.91 ± 5.995.40 ± 6.69
08

Study locations

138 sites
  • Site BY37503
    Brest, 224027, Belarus
  • Site BY37504
    Gomel, 246027, Belarus
  • Site BY37501
    Grodno, 230017, Belarus
  • Site BY37506
    Minsk, 220036, Belarus
  • Site BY37507
    Minsk, 220116, Belarus
  • Site BY37505
    Minsk, 223040, Belarus
  • Site BY37502
    Vitebsk, 210037, Belarus
  • Site BE32004
    Brussels, Flemish Brabant 1200, Belgium
  • Site BE32002
    Antwerp, 2060, Belgium
  • Site BE32012
    Baudour, 7331, Belgium
  • Site BE32017
    Bonheiden, 2820, Belgium
  • Site BE32014
    Ieper, 8900, Belgium
  • Site BE32013
    Liege, 4000, Belgium
  • Site BG35923
    Pazardjik, 4400, Bulgaria
  • Site BG35906
    Sofia, 1431, Bulgaria
  • Site BG35908
    Sofia, 1431, Bulgaria
  • Site BG35910
    Sofia, 1431, Bulgaria
  • Site BG35907
    Stara Zagora, 6000, Bulgaria
  • Site BG35916
    Varna, 9000, Bulgaria
  • Site BG35903
    Veliko Tarnovo, 5000, Bulgaria
  • Site CO57007
    Barranquilla, Colombia
  • Site CO57008
    Barranquilla, Colombia
  • Site CO57002
    Pereira, Colombia
  • Site DO17101
    La Fe Santo Domingo, 5072, Dominican Republic
  • Site DO17102
    Santiago de los Caballeros, 51000, Dominican Republic
  • Site DO17104
    Santo Domingo, 10124, Dominican Republic
  • Site DO17103
    Santo Domingo, 103201, Dominican Republic
  • Site EE37201
    Tallinn, 13419, Estonia
  • Site GE99503
    Tbilisi, 0144, Georgia
  • Site GE99504
    Tbilisi, 0144, Georgia
  • Site GE99502
    Tbilisi, 0159, Georgia
  • Site GR30003
    Heraklion, 71409, Greece
  • Site GR30002
    Patras, 26504, Greece
  • Site GR30001
    Thessaloniki, 54642, Greece
  • Site GT50209
    Chiquimula, 01001, Guatemala
  • Site GT50202
    Ciudad de Guatemala, AP 01015, Guatemala
  • Site GT50208
    Ciudad de Guatemala, CP 01001, Guatemala
  • Site GT50207
    Ciudad de Guatemala, CP 01010, Guatemala
  • Site GT50201
    Ciudad de Guatemala, CP 01016, Guatemala
  • Site GT50205
    Guatemala, 01010, Guatemala
  • Site GT50206
    Guatemala, 01010, Guatemala
  • Site GT50203
    Guatemala, 01014, Guatemala
  • Site HU36029
    Budapest, H-1036, Hungary
  • Site HU36025
    Gyor, 9002, Hungary
  • Site HU36026
    Kaposvar, H 7400, Hungary
  • Site HU36027
    Kistarcsa, 2143, Hungary
  • Site HU36008
    Pecs, H 7624, Hungary
  • Site HU36028
    Szent, H-1097, Hungary
  • Site HU36003
    Zalsaegerszeg, 8900, Hungary
  • Site IT39001
    Bari, 70124, Italy
  • Site IT39008
    Lecco, 23900, Italy
  • Site IT39006
    Milano, 20162, Italy
  • Site IT39037
    Modena, 41124, Italy
  • Site IT39036
    Pavia, 27100, Italy
  • Site PA50703
    Ciudad de Colon, 0302-00504 Z.L., Panama
  • Site PA50701
    Ciudad de Panama, Panama
  • Site PE51001
    Iquitos, 16001, Peru
  • Site PE51002
    Trujillo, 13001, Peru
  • Site PL48001
    Krakow, Malopolska 31-559, Poland
  • Site PL48002
    Katowice, 40 027, Poland
  • Site PL48012
    Lodz, 90549, Poland
  • Site PL48008
    Lodz, 92-213, Poland
  • Site PL48057
    Nowy Tomyśl, 64-300, Poland
  • Site PL48013
    Szczecin, 70-111, Poland
  • Site PL48007
    Tarnow, 33 100, Poland
  • Site PL48005
    Warszawa, 02-507, Poland
  • Site PL48004
    Warszawa, 04 749, Poland
  • Site PL48006
    Wroclaw, 50-556, Poland
  • Site PL48014
    Zamosc, 20-400, Poland
  • Site RO40005
    Timisoara, Timis 300736, Romania
  • Site RO40001
    Brasov, 500366, Romania
  • Site RO40021
    Bucharest, 022328, Romania
  • Site RO40012
    Bucuresti, 10825, Romania
  • Site RO40003
    Bucuresti, 22328, Romania
  • Site RO40004
    Oradea, 410469, Romania
  • Site RU70024
    Chelyabinsk, 454047, Russian Federation
  • Site RU70054
    Irkutsk, 664079, Russian Federation
  • Site RU70008
    Kaluga, 248007, Russian Federation
  • Site RU70051
    Moscow, 119992, Russian Federation
  • Site RU70007
    Moscow, 123182, Russian Federation
  • Site RU70005
    Moscow, 125284, Russian Federation
  • Site RU70048
    Moscow, 129301, Russian Federation
  • Site RU70047
    Moscow, 129327, Russian Federation
  • Site RU70003
    Nizhny Novgorod, 603032, Russian Federation
  • Site RU70004
    Omsk, 644112, Russian Federation
  • Site RU70043
    Petrozavodsk, 185019, Russian Federation
  • Site RU70014
    Rostov-on-don, 344029, Russian Federation
  • Site RU70022
    Saint Petersburg, 192242, Russian Federation
  • Site RU70011
    Saint Petersburg, 196247, Russian Federation
  • Site RU70002
    Saint Petersburg, 197089, Russian Federation
  • Site RU70045
    Saint-Petersburg, 194354, Russian Federation
  • Site RU70060
    Saratov, 410039, Russian Federation
  • Site RU70006
    Smolensk, 214006, Russian Federation
  • Site RU70057
    Yaroslavl, 150045, Russian Federation
  • Site RU70001
    Yaroslavl, 150062, Russian Federation
  • Site RS38102
    Belgrade, 11000, Serbia
  • Site RS38104
    Belgrade, 11000, Serbia
  • Site RS38105
    Belgrade, 11000, Serbia
  • Site RS38103
    Belgrade, 11080, Serbia
  • Site RS38117
    Krusevac, 37000, Serbia

Showing the first 100 of 138 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Little DJ, Houser MT, Frison L, Houghton J, Neff TB. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol. 2021 Aug;16(8):1190-1200. doi: 10.2215/CJN.16191020. PubMed 34362786 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Nov 2017, 49 months.

Results were first posted in Dec 2020, 3 years 1 month after primary completion. A results delay was requested in Oct 2018.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 49 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2013
First posted
Jun 27, 2013
StartActual
Sep 3, 2013
Primary completionActual
Nov 1, 2017
CompletionActual
Nov 1, 2017
Results delay requested
Oct 18, 2018
Results first posted
Dec 17, 2020
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01887600
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Jun 27, 2013
Start date
Sep 3, 2013
Primary completion
Nov 1, 2017
Completion
Nov 1, 2017
Results posted
Dec 17, 2020
Last update
Nov 14, 2024

Study contacts

Medical Monitor
study chair · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion